The Belgium-based stem cell therapy developer, which is backed by investors including Gri-Cel and Novartis, has filed to go public in the US.
TiGenix, a Belgium-based biopharmaceutical company that counts gene therapy company Gri-Cel as its largest shareholder, has filed for a $57.5m initial public offering in the US.
The IPO proceeds will be used to prepare for the commercialisation of Cx601, an injectable allogeneic stem cell therapy TiGenix is developing to combat Crohn’s disease that is currently in phase 3 trials.
Additional capital will go to completing a technology transfer to contract manufacturer Lonza to support a phase 3 trial for Cx601…
